-
PRODUCTS
- Anaesthesia & Respiratory
- Baby
- Casting
- Continence Care
-
Diagnostic
- See all Diagnostic
- Accessories
- Bladder Scanner
- Blood Testing
- Breathalyzer
- Cholesterol Testing
- Covid Testing
- Dermatoscope
- Diabetes Monitoring
- Drug Testing
- Endoscopy
- Eye Ear Nose & Throat
- Height Measures and Charts
- INR
- Jars and Containers
- Medical and Surgical Instruments
- Parts and Accessories
- Scales
- Testing
- Urinalysis
- Womens Health
- Ear Irrigation
-
Equipment
- See all Equipment
- "Miscelllaneous, Parts and Accessories"
- Beds
- Blood Collection Chair
- Bracket & Dispensers
- Carts & Trolleys
- Cryosurgery
- Electrosurgery
- Examination Couches & Tables
- Fridge & Freezers
- IV Stands
- Laundry & Cleaning Trolleys
- Play Panels
- Privacy Screens and Curtains
- Stools and Step Ups
- Stools, Bed Screens & IV Stands
- Tens
- Transferring & Patient Handling
- Waste Disposal
- X-Ray Viewers
-
General Consumables
- See all General Consumables
- "Couch Rolls, Protectors & Underpads"
- "Registers, Records and Certificates"
- Bags Assorted
- Batteries
- Blankets and Warmers
- Bracket
- Child Rewards
- Containers
- Cups
- Dental Film Process Products
- Dr Bags
- Ear Piercing
- Feminine Hygiene
- First Aid and Trauma
- Gels and Lubricants
- Identification
- Linen
- Marker
- Miscellaneous
- Ostomy
- Paper and Printing Consumables
- Paper Products
- Parts and Accessories
- Personal Care
- Pill Cutters and Crushers
- Ultrasound Gel
- Wooden Applicators
- Gloves
- Hand & Body Hygiene
-
Infection Prevention & Control
- See all Infection Prevention & Control
- Absorbent Powder
- Bedpans & Urinals
- Caps
- Clinical Sheets
- Containers
- Dispensers
- Eye Protection
- Face Masks
- Hand Hygiene
- Miscellaneous
- Parts & Accessories
- Protective Apparel
- Scrubs
- Spill Kit
- Surface Cleansers & Wipes
- Surgical Packs & Drapes
- Toileting & Waste Disposal
- Tray Liners
- Wipes and Skin Protection
- Intravenous Infusion & Administration
-
Medical & Surgical Instruments
- See all Medical & Surgical Instruments
- Biopsy Punch
- Chiropody Pliers & Podiatry
- Cleaning and Protection
- Curettes
- Dental Syringe
- Dilator
- Ear Irrigation
- Forceps
- Hammer
- Male Health
- Marker
- Miscellaneous
- Nasal Speculum
- Needle Holder
- Pack
- Probe
- Retractor
- Ring Cutter
- Scalpel Handles & Blades
- Scissors
- Skin Hook
- Sucker
- Tuning Forks
- Urology
- Uterine Curettes & Sounds
- Medical Lighting
- Medical Lighting
- Needles & Syringes
- Nutritional Support
- Oral Care
- Patient Monitoring
-
Pharmaceuticals
- See all Pharmaceuticals
- Alimentary
- Anaesthetic
- Analgesia
- Antihistamines
- Cardiovascular
- Central Nervous System
- Creams and Ointments
- Endocrine & Metabolic
- Eye Ear Nose & Throat
- Infections & Infestations
- Miscellaneous
- Musculoskeletal
- Nutrition
- Ointment Products
- Other
- Register
- Respiratory
- Skin
- Solutions
- Rehabilitation & Mobility
- Skin Care
- Sports & Recovery
-
Sterilisation
- See all Sterilisation
- Autoclaves
- Biological Indicators and incubators
- Chemical Indicator Tapes
- Chemical Indicators and Integrators
- Cleansing Solutions & Detergents
- Instrument Protector
- Labels
- Marker
- Paper and Printing Consumables
- Parts & Accessories
- Record Keeping Supplies
- Steam Indicator Sheets and Tests
- Sterilisation Pouches & Rolls
- Towels and Cloths
- Trays and Bowls
- Ultrasonic Cleaners
- Water
- Wraps
- Sutures & Skin Closures
- Urology
- Vaccines
- Wound Care
- Wound Management
AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)
INDICATION
AREXVY is indicated for active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).1
Important Information about AREXVY
Efficacy
82.6% overall efficacy against RSV-LRTD after 6.7 months follow-up*1,3 and 67.2% after 17.8 months follow-up#2 in patients 60 years and over.†1-3
*Primary endpoint, vs. placebo 82.6% (96.95% CI 57.9, 94.1). Primary objective met: lower CI limit >20%.‡
RSV-LRTD events: AREXVY 7/12,466; placebo 40/12,494.3
#Secondary confirmatory endpoint, single dose vs. placebo§ 67.2% (97.5% CI 48.2, 80.0). Secondary objective met: lower CI limit >20%.‡
RSV-LRTD events: AREXVY 30/12,469; placebo 139/12,498.2
Safety
AREXVY: an acceptable safety profile.¥2,3
¥Median follow-up post-dose 1 of 17.8 months.2, Very common adverse events (≥10%) are headache, myalgia, arthralgia, injection site pain and fatigue. Common adverse events (≥1%) are injection site erythema, injection site swelling, fever, chills and rhinorrhoea (not a complete list; see full PI). 1
Dosing and administration
AREXVY is administered as a single, reconstituted dose of 0.5 mL by intramuscular injection. The need for revaccination has not been established. 1
Storage1
- AREXVY should be refrigerated. DO NOT FREEZE (discard if frozen).1
- Store in the original package to protect vials from light.
- Store between 2°C and 8°C before reconstitution.
- After reconstitution, store between 2°C and 8°C or at room temperature up to 25°C for up to 4 hours prior to use.
- Discard reconstituted vaccine if not used within 4 hours.
†Ongoing, international, randomised, observer-blind, placebo-controlled, phase III trial to evaluate the efficacy of one dose of AREXVY (n=12,466) versus placebo (n=12,494) to prevent RSV-LRTD in adults ≥60 years of age during one RSV season (median follow-up 6.7 months, maximum follow up 10.1 months). RSV-LRTD was confirmed by RT-PCR and defined as presence for ≥24 hours of ≥2 lower respiratory symptoms or signs (including at least one sign) or ≥3 lower respiratory symptoms.3 Efficacy and safety were evaluated over two RSV seasons (median follow-up 17.8 months) of one dose of AREXVY vs. placebo and of a first dose followed by revaccination one year later vs. placebo.2
‡The criterion for meeting the primary endpoint and confirmatory secondary endpoints was a lower limit of the two-sided CI for vaccine efficacy >20%.2,3
§The co-secondary confirmatory endpoint, overall efficacy of annual revaccination vs. placebo against RSV-LRTD after 17.8 months, was met‡ (67.1%; 97.5% CI 48.1, 80.0).2
Reference Materials
REFERENCES
- AREXVY Product Information.
- Ison MG et al. Clin Infect Dis 2024;doi.org/10.1093/cid/ciae010 (Corrected proof).
- Papi A et al. N Engl J Med 2023;388(7):595–608.
Please review Product Information before prescribing. Product Information can be accessed at www.gsk.com.au/arexvy
â–¼This medicinal product is subject to additional monitoring in Australia. This will allow quick
identification of new safety information. Healthcare professionals are asked to report any suspected
adverse events at www.tga.gov.au/reporting-problems.
PBS Information: AREXVY is not listed on the PBS or the National Immunisation Program (NIP).
For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109.
Trade marks are owned by or licensed to the GSK group of companies. ©2023 GSK group of companies or its licensor.
GlaxoSmithKline Australia Pty Ltd, Melbourne, VIC.
PM-AU-RSA-WCNT-240009 | Date of approval: March 2024
Newsletter
Please enter your email address to subscribe to our newsletters.